Dopamine Synthesis Capacity Before Onset of Psychosis: A Prospective [ 18 F]-DOPA PET Imaging Study
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: While there is robust evidence of elevated dopamine synthesis capacity once a psychotic disorder has developed, little is known about whether it is altered prior to the first episode of frank illness. The authors addressed this issue by measuring dopamine synthesis capacity in individuals at ultra-high risk of psychosis and then following them to determine their clinical outcome. METHOD: This prospective study included 30 patients who met standard criteria for being at ultra-high risk of psychosis and 29 healthy volunteers. Participants were scanned using [(18)F]6-fluoro-L-dopa positron emission tomography. The ultra-high-risk patients were scanned at presentation and followed up for at least 3 years to determine their clinical outcome. Six patients had comorbid schizotypal personality disorder and were excluded from the analysis (data are provided for comparison). Of the remaining patients, nine developed a psychotic disorder (psychotic transition group) and 15 did not (nontransition group). RESULTS: There was a significant effect of group on striatal dopamine synthesis capacity. The psychotic transition group had greater dopamine synthesis capacity in the striatum (effect size=1.18) and its associative subdivision (effect size=1.24) than did the healthy comparison subjects and showed a positive correlation between dopamine synthesis capacity and symptom severity. Dopamine synthesis capacity was also significantly greater in the psychotic transition group than in the nontransition group. CONCLUSIONS: These findings provide evidence that the onset of frank psychosis is preceded by presynaptic dopaminergic dysfunction. Further research is needed to determine the specificity of elevated dopamine synthesis capacity to particular psychotic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Dopamine synthesis capacity is greater in individuals who later transition to psychosis than those who do not transition (63),”
From Aberrant Salience, Information Processing, and Dopaminergic Signaling in People at Clinical High Risk for Psychosis (2020) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
Self-citationMapping the Onset of Psychosis: The Comprehensive Assessment of At-Risk Mental States
Yung, A. R., Yung, A. R., Pan Yuen, H., Mcgorry, P. D., Phillips, L. J., Kelly, D., Dell'olio, M., Francey, S. M., Cosgrave, E. M., Killackey, E., et al. (2005) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2005.01714.x · Cited by 2,196
Dopamine in schizophrenia: a review and reconceptualization
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,018
The primate basal ganglia: Parallel and integrative networks
Haber, S. N. (2003) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2003.10.003 · Cited by 1,479
Hammers, A., Allom, R., Koepp, M. J., Free, S. L., Myers, R., Lemieux, L., Mitchell, T. N., Brooks, D. J., & Duncan, J. S. (2003) · Human Brain Mapping · doi:10.1002/hbm.10123 · Cited by 1,286
Cannon, T. D., Cadenhead, K., Cornblatt, B., Woods, S. W., Addington, J., Walker, E., Seidman, L. J., Perkins, D., Tsuang, M., McGlashan, T., et al. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.3 · Cited by 1,269
Lisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., & Grace, A. A. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.02.005 · Cited by 1,010
Elevated Striatal Dopamine Function Linked to Prodromal Signs of Schizophrenia
Howes, O. D., Montgomery, A. J., Asselin, M.-C., Murray, R. M., Valli, I., Tabraham, P., Bramon-Bosch, E., Valmaggia, L., Johns, L., Broome, M., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.514 · Cited by 744
Self-citation
Research works printed but not linked: 1
- American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994 American Psychiatric Association Press Washington DC Fourth edition
Cited by
Items 101–200 of 344
Striatal dopamine, reward, and decision making in schizophrenia
Deserno, L., Schlagenhauf, F., & Heinz, A. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.1/ldeserno · Cited by 58
Using neuroimaging to help predict the onset of psychosis
Gifford, G., Crossley, N. A., Fusar‐Poli, P., Schnack, H. G., Kahn, R. S., Koutsouleris, N., Cannon, T. D., & McGuire, P. K. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.03.075 · Cited by 67
Self-citationNeural Circuitry of Salience and Reward Processing in Psychosis
Kesby, J. P., Murray, G. K., & Knolle, F. (2023) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2021.12.003 · Cited by 55
“However, there is evidence of subcortical reward and salience dysfunction in at-risk patients, consistent with PET studies showing dopaminergic abnormalities, especially increased levels of striatal dopamine (59), early in the course of illness.”
BackgroundResultLeucht, S., Siafis, S., McGrath, J. J., McGorry, P. D., Howes, O. D., Tamminga, C. A., Carr, R., Bighelli, I., Schneider‐Thoma, J., Priller, J., et al. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00667-6 · Cited by 82
Self-citationStructural Network Disorganization in Subjects at Clinical High Risk for Psychosis
Schmidt, A., Crossley, N. A., Harrisberger, F., Smieskova, R., Lenz, C., Riecher-Rössler, A., Lang, U. E., McGuire, P., Fusar-Poli, P., & Borgwardt, S. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw110 · Cited by 55
Self-citationUrbanicity: The need for new avenues to explore the link between urban living and psychosis
Empson, L. A., Baumann, P., Söderström, O., Codeluppi, Z., Söderström, D., & Conus, P. (2019) · Early Intervention in Psychiatry · doi:10.1111/eip.12861 · Cited by 69
de Bartolomeis, A., Simone, G. D., Prisco, M. D., Barone, A., Napoli, R., Bèguinot, F., Billeci, M., & Fornaro, M. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02065-4 · Cited by 66
Badcock, J. C., & Hugdahl, K. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00180 · Cited by 53
Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis
Modinos, G., Şimşek, F., Azis, M., Bossong, M., Bonoldi, I., Samson, C., Quinn, B., Perez, J., Broome, M. R., Zelaya, F., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-017-0004-6 · Cited by 52
Self-citationNew Drug Treatments for Schizophrenia: A Review of Approaches to Target Circuit Dysfunction
Howes, O. D., Dawkins, E., Lobo, M. C., Kaar, S. J., & Beck, K. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.05.014 · Cited by 56
Self-citationSalokangas, R. K. R., Dingemans, P., Heinimaa, M., Svirskis, T., Luutonen, S., Hietala, J., Ruhrmann, S., Juckel, G., Graf von Reventlow, H., Linszen, D., et al. (2013) · European Psychiatry · doi:10.1016/j.eurpsy.2013.01.001 · Cited by 50
De Simone, G., Mazza, B., Vellucci, L., Barone, A., Ciccarelli, M., & de Bartolomeis, A. (2023) · Antioxidants · doi:10.3390/antiox12040975 · Cited by 49
Kim, E., Howes, O. D., Turkheimer, F., Kim, B., Jeong, J. M., Kim, J. W., Lee, J. S., Jang, I., Shin, S., Kapur, S., et al. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2953-0 · Cited by 60
Self-citationMolecular imaging of schizophrenia: Neurochemical findings in a heterogeneous and evolving disorder
Cumming, P. D., Abi‐Dargham, A., & Gründer, G. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113004 · Cited by 60
Gene-sex interactions in schizophrenia: focus on dopamine neurotransmission
Godar, S. C., & Bortolato, M. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00071 · Cited by 47
Neuroimaging findings in schizotypal personality disorder: A systematic review
Fervaha, G., & Remington, G. J. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.11.014 · Cited by 53
Effective Connectivity of Fronto-Striato-Thalamic Circuitry Across the Psychosis Continuum
Sabaroedin, K., Razi, A., Chopra, S., Tran, N., Pozaruk, A., Chen, Z., Finlay, A., Nelson, B., Allott, K., Álvarez‐Jiménez, M., et al. (2021) · Brain · doi:10.1016/j.biopsych.2021.02.887 · Cited by 48
McHugh, M. J., McGorry, P. D., Yung, A. R., Lin, A. P., Wood, S. J., Hartmann, J., & Nelson, B. (2016) · Psychological Medicine · doi:10.1017/s0033291716002671 · Cited by 57
Kesby, J. P., Cui, X., Burne, T. H. J., & Eyles, D. W. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00111 · Cited by 51
Dahoun, T., Nour, M. M., McCutcheon, R. A., Adams, R. A., Bloomfield, M., & Howes, O. D. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0627-y · Cited by 48
Self-citationYang, K., Longo, L., Narita, Z. C., Cascella, N. G., Nucifora, F. C., Coughlin, J. M., Nestadt, G., Sedlak, T. W., Mihaljevic, M. M., Wang, M., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01331-7 · Cited by 46
Serum immune markers and transition to psychosis in individuals at clinical high risk
Mondelli, V., Blackman, G., Kempton, M. J., Pollak, T. A., Iyegbe, C. O., Valmaggia, L., Amminger, G. P., Barrantes-Vidal, N., Bressan, R. A., van der Gaag, M., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.03.014 · Cited by 45
Self-citationde Bartolomeis, A., Vellucci, L., Austin, M. C., Simone, G. D., & Barone, A. (2022) · Biomolecules · doi:10.3390/biom12070909 · Cited by 45
Psychosis spectrum illnesses as disorders of prefrontal critical period plasticity
Vinogradov, S., Chafee, M. V., Lee, E. G., & Morishita, H. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01451-w · Cited by 55
Bauman, M. D., Lesh, T. A., Rowland, D. J., Schumann, C. M., Smucny, J., Kukis, D. L., Cherry, S. R., McAllister, A. K., & Carter, C. S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0449-y · Cited by 43
Modinos, G., Richter, A., Egerton, A., Bonoldi, I., Azis, M., Antoniades, M., Bossong, M. G., Crossley, N. A., Pérez, J. M., Stone, J. M., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01019-0 · Cited by 43
Self-citationTreatment-resistant schizophrenia: How far have we traveled?
Pandey, A., & Kalita, K. N. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.994425 · Cited by 49
Collin, G., de Nijs, J., Pol, H. E. H., Cahn, W., & van den Heuvel, M. P. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.03.012 · Cited by 45
Altered levels of dopamine transporter in the frontal pole and dorsal striatum in schizophrenia
Sekiguchi, H., Pavey, G., & Dean, B. (2019) · Schizophrenia · doi:10.1038/s41537-019-0087-7 · Cited by 42
Schmidt, A., Antoniades, M., Allen, P., Egerton, A., Chaddock, C. A., Borgwardt, S., Fusar-Poli, P., Roiser, J. P., Howes, O., & McGuire, P. (2017) · Psychological Medicine · doi:10.1017/s0033291716002439 · Cited by 38
Self-citationKindler, J., Schultze‐Lutter, F., Michel, C., Martz-Irngartinger, A., Linder, C., Schmidt, S. J., Stegmayer, K., SCHIMMELMANN, B. G., & Walther, S. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.04.032 · Cited by 42
Barnby, J. M., Deeley, Q., Robinson, O. J., Raihani, N., Bell, V., & Mehta, M. A. (2020) · Royal Society Open Science · doi:10.1098/rsos.191525 · Cited by 42
Krashia, P., Ledonne, A., Nobili, A., Cordella, A., Errico, F., Usiello, A., D’Amelio, M., Mercuri, N. B., Guatteo, E., & Carunchio, I. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.013 · Cited by 41
Bloemen, O. J. N., de Koning, M. B., Gleich, T., Meijer, J., de Haan, L., Linszen, D. H., Booij, J., & van Amelsvoort, T. A. M. J. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.04.015 · Cited by 37
Wulff, S., Pinborg, L. H., Svarer, C., Jensen, L. T., Nielsen, M. Ø., Allerup, P., Bak, N. K., Rasmussen, H., Frandsen, E., Rostrup, E., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu220 · Cited by 40
Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia
Sonnenschein, S. F., & Grace, A. A. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.009 · Cited by 40
Howes, O. D., Bonoldi, I., McCutcheon, R. A., Azis, M., Antoniades, M., Bossong, M. G., Modinos, G., Pérez, J. M., Stone, J. M., Santangelo, B., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0541-2 · Cited by 39
Self-citationMcCutcheon, R. A., Merritt, K., & Howes, O. D. (2021) · World Psychiatry · doi:10.1002/wps.20893 · Cited by 54
Self-citationPsychotic disorders as a framework for precision psychiatry
Coutts, F., Koutsouleris, N., & McGuire, P. K. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00779-1 · Cited by 57
Self-citationPre-pulse inhibition and striatal dopamine in subjects at an ultra-high risk for psychosis
de Koning, M. B., Bloemen, O., van Duin, E. D. A., Booij, J., Abel, K. M., de Haan, L., LINSZEN, D. H., & van Amelsvoort, T. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113519507 · Cited by 38
Emerging Temporal Lobe Dysfunction in People at Clinical High Risk for Psychosis
Allen, P., Moore, H. M., Corcoran, C. M., Gilleen, J., Kozhuharova, P., Reichenberg, A., & Malaspina, D. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00298 · Cited by 42
Predictive validity of conversion from the clinical high risk syndrome to frank psychosis
Sykes, L. Y., Ferrara, M., Addington, J., Bearden, C. E., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., Perkins, D. O., Mathalon, D. H., Seidman, L. J., et al. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.12.002 · Cited by 36
Sabaroedin, K., Tiego, J., & Fornito, A. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.07.017 · Cited by 36
Can neuroimaging be used to predict the onset of psychosis?
McGuire, P. K., Sato, J. R., Mechelli, A., Jackowski, A. P., Bressan, R. A., & Zugman, A. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00308-9 · Cited by 38
Self-citationThe effect of perinatal brain injury on dopaminergic function and hippocampal volume in adult life
Froudist‐Walsh, S., Bloomfield, M., Veronese, M., Kroll, J., Karolis, V. R., Jauhar, S., Bonoldi, I., McGuire, P. K., Kapur, S., Murray, R. M., et al. (2017) · eLife · doi:10.7554/elife.29088 · Cited by 38
Self-citationAberrant Temporal Connectivity in Persons at Clinical High Risk for Psychosis
Colibazzi, T., Yang, Z., Horga, G., Yan, C., Corcoran, C. M., Klahr, K., Brucato, G., Girgis, R. R., Abi‐Dargham, A., Milham, M. P., et al. (2017) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2016.12.008 · Cited by 40
Rogdaki, M., Devroye, C., Ciampoli, M., Veronese, M., Ashok, A. H., McCutcheon, R. A., Jauhar, S., Bonoldi, I., Gudbrandsen, M., Daly, E., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01108-y · Cited by 39
Self-citationCervenka, S., Frick, A., Bodén, R., & Lubberink, M. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01990-2 · Cited by 32
Mapping the Psychotic Mind: a Review on the Subjective Structure of Thought Insertion
López‐Silva, P. (2018) · Psychiatric Quarterly · doi:10.1007/s11126-018-9593-4 · Cited by 34
Nigral stress-induced dopamine release in clinical high risk and antipsychotic-naïve schizophrenia
Tseng, H.-H., Watts, J. J., Kiang, M., Suridjan, I., Wilson, A. A., Houle, S., Rusjan, P. M., & Mizrahi, R. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx042 · Cited by 31
Ceaser, A. E., & Barch, D. M. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2015.00687 · Cited by 30
Diwadkar, V. A., Bustamante, A. C., Rai, H., & Uddin, M. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00071 · Cited by 31
Novel Compounds in the Treatment of Schizophrenia—A Selective Review
Diakaki, K., Miliaras, A., Tsapakis, E.-M., & Fountoulakis, K. Ν. (2023) · Brain Sciences · doi:10.3390/brainsci13081193 · Cited by 37
Neuroimaging Findings in the At-Risk Mental State: A Review of Recent Literature
Wood, S. J., Reniers, R. L. E. P., & Heinze, K. (2013) · The Canadian Journal of Psychiatry · doi:10.1177/070674371305800104 · Cited by 37
Chestnykh, D., Amato, D., Kornhuber, J., & Müller, C. P. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113144 · Cited by 35
Antipsychotic Interventions in Prodromal Psychosis: Safety Issues
Liu, C., & Demjaha, A. (2013) · CNS Drugs · doi:10.1007/s40263-013-0046-1 · Cited by 33
Olfaction in the psychosis prodrome: Electrophysiological and behavioral measures of odor detection
Kayser, J., Tenke, C. E., Kroppmann, C. J., Alschuler, D. M., Ben‐David, S., Fekri, S. M., Bruder, G. E., & Corcoran, C. M. (2013) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2013.07.003 · Cited by 29
D’Ambrosio, E., Jauhar, S., Kim, S., Veronese, M., Rogdaki, M., Pepper, F., Bonoldi, I., Kotoula, V., Kempton, M. J., Turkheimer, F., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0570-6 · Cited by 29
Self-citationEllis, J. K., Walker, E. F., & Goldsmith, D. R. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.567534 · Cited by 31
Reinforcement Learning Performance and Risk for Psychosis in Youth
Waltz, J. A., Demro, C., Schiffman, J. E., Thompson, E., Kline, E. R., Reeves, G. M., Xu, Z., & Gold, J. M. (2015) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000420 · Cited by 28
The EPOS Group, Salokangas, R. K. R., Schultze‐Lutter, F., Hietala, J. A., Heinimaa, M., From, T., Ilonen, T., Löyttyniemi, E., von Reventlow, H. G., Juckel, G., et al. (2015) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-015-1160-9 · Cited by 34
The Prodrome and Clinical Risk for Psychotic Disorders
Goulding, S. M., Holtzman, C. W., Trotman, H. D., Ryan, A. T., MacDonald, A. N., Shapiro, D. I., Brasfield, J. L., & Walker, E. F. (2013) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2013.04.002 · Cited by 33
Common Variation in the DOPA Decarboxylase (DDC) Gene and Human Striatal DDC Activity In Vivo
Eisenberg, D. P., Kohn, P. D., Hegarty, C. E., Ianni, A. M., Kolachana, B. S., Gregory, M. D., Masdeu, J. C., & Berman, K. F. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.31 · Cited by 24
McCollum, L. A., & Roberts, R. C. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.08.041 · Cited by 31
Hubl, D., Schultze‐Lutter, F., Hauf, M., Dierks, T., Federspiel, A., Kaess, M., Michel, C., SCHIMMELMANN, B. G., & Kindler, J. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.06.018 · Cited by 30
Is Dopamine Neurotransmission Altered in Prodromal Schizophrenia? A Review of the Evidence
Bauer, M., Praschak-Rieder, N., Kasper, S. F., & Willeit, M. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799958611 · Cited by 28
Karcher, N. R., Martin, E. A., & Kerns, J. G. (2015) · Journal of Abnormal Psychology · doi:10.1037/abn0000067 · Cited by 25
Wengler, K., Baker, S. C., Velikovskaya, A., Fogelson, A., Girgis, R. R., Reyes-Madrigal, F., Lee, S., de la Fuente‐Sandoval, C., Ojeil, N., & Horga, G. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.4305 · Cited by 23
Chen, L., Perez, S. M., & Lodge, D. J. (2014) · Developmental Neurobiology · doi:10.1002/dneu.22172 · Cited by 27
Abi‐Dargham, A. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.12.003 · Cited by 25
de Bartolomeis, A., Simone, G. D., Ciccarelli, M., Castiello, A., Mazza, B., Vellucci, L., & Barone, A. (2022) · Biomedicines · doi:10.3390/biomedicines10123183 · Cited by 26
Association of neurotransmitter pathway polygenic risk with specific symptom profiles in psychosis
Warren, T. L., Tubbs, J. D., Lesh, T. A., Corona, M. B., Pakzad, S., Albuquerque, M., Singh, P., Zarubin, V. C., Morse, S. J., Sham, P. C., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02457-0 · Cited by 26
Sonnenschein, S. F., & Grace, A. A. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1849144 · Cited by 24
Automated Data Quality Control in FDOPA brain PET Imaging using Deep Learning
Pontoriero, A. D., Nordio, G., Easmin, R., Giacomel, A., Santangelo, B., Jauhar, S., Bonoldi, I., Rogdaki, M., Turkheimer, F., Howes, O. D., et al. (2021) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2021.106239 · Cited by 27
Self-citationHernaus, D., Collip, D., Lataster, J., Viechtbauer, W., Myin, E., Ceccarini, J., Laere, K. V., van Os, J., & Myin‐Germeys, I. (2015) · Journal of Abnormal Psychology · doi:10.1037/abn0000010 · Cited by 32
Petty, A. E., Cui, X., Tesiram, Y. A., Kirik, D., Howes, O. D., & Eyles, D. W. (2019) · Schizophrenia · doi:10.1038/s41537-019-0074-z · Cited by 28
Self-citationSolis, M. (2014) · Nature · doi:10.1038/508s12a · Cited by 22
Kim, E., Shidahara, M., Tsoumpas, C., McGinnity, C. J., Kwon, J. S., Howes, O. D., & Turkheimer, F. E. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.29 · Cited by 22
Self-citationMolecular imaging as a guide for the treatment of central nervous system disorders
Kim, E., Howes, O. D., & Kapur, S. (2013) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2013.15.3/ekim · Cited by 27
Self-citationSalience attribution and its relationship to cannabis-induced psychotic symptoms
Bloomfield, M., Mouchlianitis, E. D., Morgan, C. J. A., Freeman, T. P., Curran, H. V., Roiser, J. P., & Howes, O. D. (2016) · Psychological Medicine · doi:10.1017/s0033291716002051 · Cited by 24
Self-citationWang, C., Lee, J., Ho, N. F., Lim, J. K. W., Poh, J. S., Rekhi, G., Krishnan, R. K. R., Keefe, R. S. E., Adcock, R. A., Wood, S. J., et al. (2017) · Cerebral Cortex · doi:10.1093/cercor/bhx278 · Cited by 22
Redman, S. L., Corcoran, C. M., Kimhy, D., & Malaspina, D. (2017) · PubMed · Cited by 23
Recent Developments in Molecular Brain Imaging of Neuropsychiatric Disorders
Slifstein, M., & Abi‐Dargham, A. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.002 · Cited by 25
Glutamatergic metabolites among adolescents at risk for psychosis
Demro, C., Rowland, L. M., Wijtenburg, S. A., Waltz, J. A., Gold, J. M., Kline, E. R., Thompson, E., Reeves, G. M., Hong, L. E., & Schiffman, J. E. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.07.040 · Cited by 19
Kim, S., Jung, W. H., Howes, O. D., Veronese, M., Turkheimer, F., Lee, Y., Lee, J. S., Kim, E., & Kwon, J. S. (2018) · Psychological Medicine · doi:10.1017/s0033291718003471 · Cited by 24
Self-citationThe prodromal phase of psychosis
Modinos, G., & McGuire, P. K. (2014) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.11.003 · Cited by 24
Self-citationChen, Y., Gu, Y., Wang, B., Wei, A., Dong, N., Jiang, Y. Q., Liu, X., Zhu, L., Zhu, F., Tan, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54604-4 · Cited by 21
D’Ambrosio, E., Dahoun, T., Pardiñas, A. F., Veronese, M., Bloomfield, M., Jauhar, S., Bonoldi, I., Rogdaki, M., Froudist‐Walsh, S., Walters, J., et al. (2019) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2019.07.005 · Cited by 23
Self-citationPotkin, S. G., Kane, J. M., Correll, C. U., Lindenmayer, J., Agid, O., Marder, S. R., Olfson, M., & Howes, O. D. (2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.18309 · Cited by 23
Self-citationAltered G Protein Coupling in Olfactory Neuroepithelial Cells From Patients With Schizophrenia
Borgmann‐Winter, K. E., Wang, H.-Y., Ray, R., Willis, B. R., Moberg, P. J., Rawson, N. E., Gur, R. E., Turetsky, B. I., & Hahn, C.-G. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv129 · Cited by 20
Sportelli, L., Eisenberg, D. P., Passiatore, R., D’Ambrosio, E., Antonucci, L. A., Bettina, J. S., Chen, Q., Goldman, A. L., Gregory, M. D., Griffiths, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47456-5 · Cited by 24
Self-citationThe Enduring Centrality of Dopamine in the Pathophysiology of Schizophrenia
Bonoldi, I., & Howes, O. D. (2013) · Advances in pharmacology · doi:10.1016/b978-0-12-411512-5.00010-5 · Cited by 20
Self-citationAn automatic analysis framework for FDOPA PET neuroimaging
Nordio, G., Easmin, R., Giacomel, A., Dipasquale, O., Martins, D., Williams, S., Turkheimer, F., Howes, O. D., Veronese, M., and the FDOPA PET imaging working group:, et al. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231168687 · Cited by 19
Self-citationDopaminergic function in relation to genes associated with risk for schizophrenia
Moran, P. M., O’Tuathaigh, C. M. P., Papaleo, F., & Waddington, J. L. (2014) · Progress in brain research · doi:10.1016/b978-0-444-63425-2.00004-0 · Cited by 20
Angelescu, I., Kaar, S. J., Marques, T. R., Borgan, F., Veronesse, M., Sharman, A., Sajjala, A., Deakin, J. F. W., Hutchison, J., Large, C. H., et al. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221122031 · Cited by 18
Self-citationGirgis, R. R., Slifstein, M., Brucato, G., Kegeles, L. S., Colibazzi, T., Lieberman, J. A., & Abi‐Dargham, A. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-00934-w · Cited by 19
Plitman, E., Chavez, S., Nakajima, S., Iwata, Y., Chung, J. K., Caravaggio, F., Kim, J., Alshehri, Y., Chakravarty, M. M., Luca, V. D., et al. (2018) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2018.01.004 · Cited by 19
Kawaguchi, H., Obata, T., Takano, H., Nogami, T., Suhara, T., & Ito, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087886 · Cited by 16
Antipsychotics and the Dopamine–Serotonin Connection
Ellenbroek, B. A., & Cesura, A. M. (2014) · Topics in medicinal chemistry · doi:10.1007/7355_2014_51 · Cited by 21
Badawy, A. A. ‐. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3191-9 · Cited by 15
Metadata
- Authors
- Howes, O. D., Bose, S. K., Turkheimer, F., Valli, I., Egerton, A., Valmaggia, L. R., Murray, R. M., & McGuire, P.
- Affiliations
- King's College London (GB)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2011-12
- Volume
- 168
- Issue
- 12
- Pages
- 1311-1317
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- PMC
- PMC3682447
- OpenAlex
- W2143870537
- Cited by
- 343
- References
- 40
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 16 · 2023: 17 · 2022: 24 · 2021: 17 · 2020: 29 · 2019: 30 · 2018: 20 · 2017: 22 · 2016: 37 · 2015: 21 · 2014: 27 · 2013: 31 · 2012: 26
- FWCI
- 18.93
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- South London and Maudsley NHS Foundation Trust
- Medical Research Council
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- dopamine synthesis capacity, clinical high risk for psychosis, first-episode psychosis, striatum, 18F-DOPA PET, symptom severity, schizophrenia, schizotypal personality disorder
- MeSH terms
- Adult, Brain, Corpus Striatum, Dopamine, Female, Humans, Male, Prospective Studies, Psychotic Disorders, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.